Florida Senate - 2024 SB 1320 By Senator Calatayud 38-00635-24 20241320__ 1 A bill to be entitled 2 An act relating to HIV infection prevention drugs; 3 creating s. 465.1861, F.S.; defining terms; 4 authorizing pharmacists to screen adults for HIV 5 exposure and provide the results to such adults; 6 requiring pharmacists to advise individuals to seek 7 consultation and treatment from a physician if the 8 screening results are positive; authorizing 9 pharmacists to order and dispense HIV infection 10 prevention drugs only pursuant to a collaborative 11 practice agreement with a physician; requiring 12 pharmacists to be certified by the Board of Pharmacy 13 before ordering and dispensing HIV infection 14 prevention drugs; requiring the board, in consultation 15 with the Board of Medicine and the Board of 16 Osteopathic Medicine, to adopt rules for such 17 certification; specifying minimum requirements for the 18 certification; requiring the board to adopt rules; 19 providing an effective date. 20 21 Be It Enacted by the Legislature of the State of Florida: 22 23 Section 1. Section 465.1861, Florida Statutes, is created 24 to read: 25 465.1861 Ordering and dispensing HIV drugs.— 26 (1) As used in this section, the term: 27 (a) “HIV” means the human immunodeficiency virus. 28 (b) “HIV infection prevention drug” means preexposure 29 prophylaxis, postexposure prophylaxis, and any other drug 30 approved by the United States Food and Drug Administration for 31 the prevention of HIV infection as of March 8, 2024. 32 (c) “Postexposure prophylaxis” means a drug or drug 33 combination that meets the clinical eligibility recommendations 34 of the United States Centers for Disease Control and Prevention 35 guidelines for antiretroviral treatment following potential 36 exposure to HIV issued as of March 8, 2024. 37 (d) “Preexposure prophylaxis” means a drug or drug 38 combination that meets the clinical eligibility recommendations 39 of the United States Centers for Disease Control and Prevention 40 guidelines for antiretroviral treatment for the prevention of 41 HIV transmission issued as of March 8, 2024. 42 (2) A pharmacist may screen an adult for HIV exposure and 43 provide the results to that adult. If the results of the 44 screening are positive, the pharmacist must advise the patient 45 that he or she should seek further medical consultation or 46 treatment from a physician. 47 (3) A pharmacist may order and dispense HIV infection 48 prevention drugs only pursuant to a collaborative practice 49 agreement between the pharmacist and a physician licensed under 50 chapter 458 or chapter 459. 51 (4) Before ordering or dispensing HIV infection prevention 52 drugs under this section, a pharmacist must be certified by the 53 board, according to the rules adopted by the board, in 54 consultation with the Board of Medicine and the Board of 55 Osteopathic Medicine. To be certified, a pharmacist must, at a 56 minimum, meet all of the following criteria: 57 (a) Hold an active and unencumbered license to practice 58 pharmacy under this chapter. 59 (b) Be engaged in the active practice of pharmacy. 60 (c) Have earned a degree of doctor of pharmacy or have 61 completed at least 5 years of experience as a licensed 62 pharmacist. 63 (d) Maintain at least $250,000 of liability coverage. A 64 pharmacist who maintains liability coverage pursuant to s. 65 465.1865 or s. 465.1895 satisfies this requirement. 66 (e) Have completed a course approved by the board, in 67 consultation with the Board of Medicine and the Board of 68 Osteopathic Medicine, which includes, at a minimum, instruction 69 on all of the following: 70 1. Performance of patient assessments. 71 2. Point-of-care testing procedures. 72 3. Safe and effective treatment of HIV exposure with HIV 73 infection prevention drugs, including, but not limited to, 74 consideration of the side effects of the drug dispensed and the 75 patient’s diet and activity levels. 76 4. Identification of contraindications. 77 5. Identification of patient comorbidities in individuals 78 with HIV requiring further medical evaluation and treatment, 79 including, but not limited to, cardiovascular disease, lung and 80 liver cancer, chronic obstructive lung disease, and diabetes 81 mellitus. 82 (5) The board shall adopt rules to implement this section. 83 Section 2. This act shall take effect July 1, 2024.